Obesity Medicine

 
The 10 States with the Highest Risk for Cancer
March 21, 2025

The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.

Investigational Keto Diet Pill Shows Promise in Phase 1 Trial: Daily Dose
March 21, 2025

Your daily dose of the clinical news you may have missed.

ZUPREME-1 Phase 2b Trial of Petrelentide for Obesity Completes Enrollment
March 19, 2025

The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.

Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
March 14, 2025

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 Trial
March 11, 2025

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

Investigational Ketogenic Diet Pill BL-001 Shows Significant Weight Loss in Phase 1 Trial
March 05, 2025

Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.

Obesity Will Affect One-Half of Adults, One-Third of Youth Worldwide by 2050
March 04, 2025

Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.

Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
February 26, 2025

Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.

Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines
February 07, 2025

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
February 06, 2025

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.